In summary, we identified recurrent RET fusions in CRC and we validated ponatinib’s ability to target these fusions in a RET-specific manner that meets or exceeds a standard of care chemotherapy agent in clinically relevant in vivo models. The gene discussed is RET; the disease is colorectal carcinoma.